CD39 and CD73 in immunity and inflammation.

CD39 and CD73 in immunity and inflammation.
复制标题

DOI:
10.1016/j.molmed.2013.03.005
复制
发表时间:
2013-06
影响因子:
13.6
通讯作者:
Haskó G
Haskó G
中科院分区:
医学1区
文献类型:
--
作者:
Antonioli L;Pacher P;Vizi ES;Haskó G

文献摘要

参考文献

被引文献

相似文献

CD39和CD73的酶活性分别通过将ADP/ATP转化为AMP和AMP转化为腺苷,在调节递送给免疫细胞的嘌呤能信号的持续时间、幅度和化学性质方面发挥着重要作用。这推动了从ATP驱动的促炎环境向腺苷诱导的抗炎环境的转变。CD39/CD73通路随其所处的病理生理环境而动态变化。越来越多的人认识到,改变这种分解代谢机制可以改变几种病理生理事件的过程或结果,如艾滋病、自身免疫性疾病、感染、动脉粥样硬化、缺血再灌注损伤和癌症,这表明这些胞外酶是管理各种疾病的新的治疗靶点。
The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ecto-enzymes are novel therapeutic targets for managing a variety of disorders.
DOI: 10.3109/13813455.2012.755547
发表时间: 2013-05-01
影响因子: 3
作者:
Burghoff, Sandra;Floegel, Ulrich;Schrader, Juergen
通讯作者: Schrader, Juergen
DOI: 10.1182/blood-2006-12-064527
发表时间: 2007-08-15
期刊: BLOOD
影响因子: 20.3
作者:
Borsellino, Giovanna;Kleinewietfeld, Markus;Falk, Kirsten
通讯作者: Falk, Kirsten
DOI: 10.1016/j.immuni.2011.12.019
发表时间: 2012-03-23
期刊: IMMUNITY
影响因子: 32.4
作者:
Chalmin, Fanny;Mignot, Gregoire;Ghiringhelli, Francois
通讯作者: Ghiringhelli, Francois
DOI: 10.4049/jimmunol.1003884
发表时间: 2011-07-15
影响因子: 4.4
作者:
Clayton, Aled;Al-Taei, Saly;Tabi, Zsuzsanna
通讯作者: Tabi, Zsuzsanna
DOI: 10.1182/blood.v88.5.1755.bloodjournal8851755
发表时间: 1996-09-01
期刊: BLOOD
影响因子: 20.3
作者:
Airas, L;Jalkanen, S
通讯作者: Jalkanen, S